Regenerative Fibroblast Therapy for Stroke and TBI Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for stroke and traumatic brain injury (TBI) are limited, with less than 20% of ischemic stroke patients receiving effective treatment, and secondary inflammatory responses exacerbate brain injury, while TBI often goes undiagnosed and untreated, leading to significant long-term disabilities and deaths.
Innovation Solution
Administration of regenerative fibroblasts, which can be derived from various tissues and engineered to produce growth factors like VEGF, BDNF, and NGF, to induce neural stem cell proliferation and promote healing responses in the brain, either systemically or locally, to treat or prevent conditions such as stroke, TBI, and tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombolysis and thrombectomy are used for ischemic stroke, then treatment effectiveness is improved, but the number of patients who can receive treatment is limited to less than 20%
Solution Approach 1:
The patent uses anti-inflammatory agents as intermediary substances to mediate between the ischemic injury and the healing process. These agents target the secondary inflammatory response that exacerbates brain damage, providing a therapeutic mechanism that works through a different pathway than direct thrombolysis, thereby expanding treatment options to patients who cannot receive thrombolytic therapy
Solution Approach 2:
The patent shifts the therapeutic parameter from targeting the primary vascular occlusion (thrombolysis) to targeting the secondary inflammatory response (anti-inflammatory agents). This parameter change allows treatment of patients who are ineligible for thrombolysis due to timing, contraindications, or anatomical factors, while still addressing the underlying pathology that drives secondary brain injury
2Reliability
If restrictive inclusion criteria are applied for stroke treatment, then treatment safety is improved, but the number of treatable patients decreases to less than 20%
Solution Approach 1:
The patent develops anti-inflammatory agents with broad applicability that can treat multiple types of brain injury including ischemic stroke, hemorrhagic stroke, and traumatic brain injury. This universal therapeutic approach eliminates the need for restrictive inclusion criteria specific to thrombolysis, allowing treatment of a much broader patient population while maintaining safety through targeted anti-inflammatory mechanisms
Solution Approach 2:
Instead of trying to prevent inflammation (the harmful secondary response), the patent inverts the approach by actively treating the inflammatory response itself as the primary target. This inversion allows treatment of patients who would otherwise be excluded from thrombolysis, as the therapeutic mechanism works through a different physiological pathway that is safer for broader application
3Loss of time
If secondary inflammatory responses are allowed to proceed naturally, then the body's natural healing process is maintained, but infarct size increases and clinical outcome worsens
Solution Approach 1:
The patent converts the harmful secondary inflammatory response into a beneficial therapeutic target. By developing anti-inflammatory agents that specifically modulate the inflammatory cascade, the treatment transforms the body's natural but harmful inflammatory response into an opportunity for therapeutic intervention that reduces infarct size and improves outcomes while still allowing the natural healing process to proceed
Solution Approach 2:
The patent applies preliminary anti-action by administering anti-inflammatory agents to prevent the exacerbation of brain injury that would otherwise occur through secondary inflammation. This preliminary intervention blocks the harmful inflammatory cascade before it can cause additional damage, while still allowing the essential natural healing processes to continue
4Device complexity
If TBI diagnosis and treatment are delayed, then initial assessment complexity is reduced, but long-term disabilities and deaths increase significantly
Solution Approach 1:
The patent implements preliminary action by establishing protocols for early administration of anti-inflammatory agents in TBI patients. This preliminary treatment approach does not require complex delayed assessments, as the therapeutic intervention is initiated based on initial trauma assessment, thereby preventing secondary inflammatory damage before it occurs and improving long-term outcomes
Data Source
Figure 1
AI summary
Disclosed are methods, compositions of matter, and means of treatment or prophylaxis using fibroblasts possessing regenerative properties for the treatment of brain injuries including stroke, transient ischemic injuries, chronic traumatic encephalopathy, traumatic brain injury, and tauopathies. Embodiments of the disclosure administer fibroblasts with regenerative properties either systemically, locally, or a combination of the two prior to, concurrent with, or subsequent to a brain injury. In some embodiments of the disclosure fibroblasts or products thereof, are administered intranasally, intrathecally, and/or intravenously.